

- 11:00 6. Kinase By-pass: A New Strategy for Antiviral Drug Discovery. C. McGuigan, R.N. Pathirana, P. Bellevergue, M.Davies, N. Mahmood, and A.J. Hay. *University of Southampton, Southampton; MRC Collaborative Centre, Mill Hill; and National Institute for Medical Research, London, UK.*
- 11:15 7. Novel Chiral Isomeric Nucleosides and Nucleotides: Synthesis, Enzymology and Anti-HIV Activity. V. Nair, L.B. Zintek, T.B. Sells, A.L. Jeffery, Z.M. Nuesca, D.F. Purdy, G.S. Jeon, R.B. Hamilton, P.J. Bolon, and S. Malany. *University of Iowa, Iowa City, Iowa, USA.*
- 11:30 8. Synthesis of Novel Oxathiolane and Dithiolane Nucleoside Analogues Possessing Anti-HIV Activity. N. Nguyen-Ba, L. Brasili, W.L. Brown, L. Chan, B. Zacharie, N. Lee, M. DiMarco, D. Lafleur, B. Belleau, P. Hopewell, and N. Cammack. *Bio Chem Therapeutic, Inc., Laval, Canada; and Glaxo Group Research, Ltd., Greenford, Middlesex, UK.*
- 11:45 9. Enantiomeric DDC Derivatives are Potent Inhibitors of HIV Replication in Cell Cultures. J.-L. Imbach, G. Gosselin, C. Math, M.-C. Bergogne, R.F. Schinazi, J.P. Sommadossi, A. Kirn, and A.-M. Aubertin. *Universit  de Montpellier II, France; Emory University, Atlanta, GA; University of Alabama, Birmingham, AL, USA; and Universit  Louis Pasteur, Strasbourg, France.*
- 12:00 Lunch

Oral Session II: Herpesvirus Infections I

Chairpersons: C.A. Laughlin and S.L. Sacks

- 1:30pm Plenary Speaker - Norbert Bischofberger
"Development of Nucleotide Prodrugs as Antiviral Agents"
GileadSciences, Inc. Foster City, CA, USA
- 2:00 10. Preclinical Evaluation of a Phosphorothioate Oligonucleotide with Potent Antiviral Activity against Human Cytomegalovirus. K.P. Anderson, R.F. Azad, V.B. Driver, H. Zhang, P. Cossum, J. Leeds, and D. Kornbrust. *ISIS Pharmaceuticals, Carlsbad, CA, USA.*
- 2:15 11. Antiviral Activity of Acyclic Nucleotide Phosphonate Analogs Derived from Azapurine Bases. A. Holy, H. Dvorakova, D. Hockova, J. Balzarini, R. Snoeck, and E. De Clercq. *Institute of Organic Chemistry and Biochemistry, Prague, The Czech Republic; and Katholieke Universiteit Leuven, Leuven, Belgium.*

- 2:30 12. Comparison of Anti-HSV Activity and Metabolism of Acyclic Nucleotide Analogs. P. Aduma, M. Connelly, N. Bischofberger, and A. Fridland. *St. Jude Children's Research Hospital, Memphis, TN; and Gilead Sciences, Foster City, CA, USA.*
- 2:45 13. Phosphonate Derivatives of Ganciclovir and Acyclovir Inhibit Murine Cytomegalovirus (MCMV) Infections in Cell Culture and in Mice. D.F. Smee, S.T. Sugiyama, J.H. Huffman, N. Zaveri, and E.J. Reist. *Utah State University, Logan, UT; and SRI International, Menlo Park, CA, USA.*
- 3:00 14. Treatment of Viral Retinitis with High Dose HPMPC Liposomes. M. Flores-Aguilar, G. Besen, and W.R. Freeman. *University of California, San Diego, Shiley Eye Center, La Jolla, CA, USA*
- 3:15 15. Clinical Trials of (S)-1-[3-Hydroxy-2-(phosphonylmethoxy) propyl]cytosine (HPMPC). H.S. Jaffe. *Gilead Sciences, Inc., Foster City, CA, USA.*
- 3:30 16. In Vivo Anti-Herpesvirus Activity of the N7-Isomeric Acyclic Nucleoside Analogue 2242 and its Prodrug HOE 961. J. Neyts, I. Winkler, G. Jähne, and E. De Clercq. *Katholieke Universiteit Leuven, Leuven, Belgium; and Hoechst AG, Frankfurt am Main, Germany*
- 3:45 17. Evaluation of Retinal Toxicity of the anti-CMV Compound 2-Amino-7-[(1,3-dihydroxy-2-propoxy) methyl]purine. G. Besen, G. Jähne, I. Winkler, M. Helsberg, D. Munguia, B. Chandler, P. Gangan, G. Bergeron-Lynn, and W.R. Freeman. *University of California, San Diego, Shiley Eye Center, La Jolla, CA, USA; and Hoechst AG, Frankfurt am Main, Germany.*
- 4:00 18. Pharmacokinetics and Bioavailability of Cygalovir (BMS-180194) in Asymptomatic HIV- and CMV-Seropositive Volunteers. B.G. Petty, H. Saito, R.S. Summerill, H. Burgee, J. McDowell, and M.B. Stewart. *The Johns Hopkins University School of Medicine, Baltimore, MD; and Bristol-Myers Squibb PRI, Princeton, NJ and Syracuse, NY, USA.*
- 4:15 19. Oral vs Intravenous Ganciclovir (GCV) as Maintenance Treatment of Newly Diagnosed Cytomegalovirus Retinitis (CMVR) in AIDS. J.P. Lalezari and the Syntex Cooperative Oral GCV Study Group. *Mt. Zion Medical Center of University of California, San Francisco, CA, USA.*